Avalyn Pharma (NASDAQ:AVLN) Shares Gap Up – Should You Buy?

Avalyn Pharma Inc. (NASDAQ:AVLN) shares gapped up prior to trading on Tuesday . The stock had previously closed at $33.57, but opened at $35.01. Avalyn Pharma shares last traded at $34.46, with a volume of 5,918 shares trading hands.

Wall Street Analyst Weigh In

A number of research firms have recently commented on AVLN. Jefferies Financial Group initiated coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $52.00 price objective for the company. Wall Street Zen upgraded shares of Avalyn Pharma from a “sell” rating to a “hold” rating in a report on Saturday. Zacks Research raised shares of Avalyn Pharma to a “hold” rating in a research report on Wednesday, May 27th. Guggenheim initiated coverage on shares of Avalyn Pharma in a research note on Monday, May 25th. They set a “buy” rating and a $80.00 price target on the stock. Finally, Evercore started coverage on shares of Avalyn Pharma in a report on Tuesday, May 26th. They issued an “outperform” rating and a $51.00 price target on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, two have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Avalyn Pharma Price Performance

The company has a quick ratio of 33.12, a current ratio of 33.12 and a debt-to-equity ratio of 0.04. The stock’s 50-day moving average is $32.94. The firm has a market capitalization of $1.47 billion and a PE ratio of -1.45.

Avalyn Pharma (NASDAQ:AVLN) last released its quarterly earnings data on Wednesday, August 12th. The company reported ($0.98) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.03) by $0.05. As a group, sell-side analysts expect that Avalyn Pharma Inc. will post -3.81 EPS for the current year.

Institutional Trading of Avalyn Pharma

Several large investors have recently added to or reduced their stakes in the stock. Montanova Capital LLC purchased a new position in Avalyn Pharma in the second quarter valued at about $82,402,000. Braidwell LP purchased a new stake in shares of Avalyn Pharma in the second quarter worth about $26,382,000. Bank of New York Mellon Corp purchased a new stake in shares of Avalyn Pharma in the second quarter worth about $1,321,000. Finally, California State Teachers Retirement System acquired a new stake in shares of Avalyn Pharma in the second quarter valued at about $236,000.

Avalyn Pharma Company Profile

Avalyn Pharma is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for serious and progressive pulmonary diseases. The company is working to deliver established antifibrotic medicines directly to the lungs through proprietary inhalation technologies, with the goal of improving treatment and potentially reducing systemic exposure and related side effects.

Avalyn’s lead program, AP01, is an inhaled formulation of pirfenidone being developed for patients with idiopathic pulmonary fibrosis, a chronic lung disease characterized by progressive scarring and declining respiratory function.